Skip to content
The Lifesciences Magazine Logo
  • About Us
  • Magazines
  • Blogs
    • HealthTech
    • Lifesciences
    • Pharma
    • Healthcare
    • Fitness
    • Nutrition
  • Contact Us
  • About Us
  • Magazines
  • Blogs
    • HealthTech
    • Lifesciences
    • Pharma
    • Healthcare
    • Fitness
    • Nutrition
  • Contact Us
Linkedin X-twitter Medium Reddit
  • About Us
  • Magazines
  • Blogs
    • HealthTech
    • Lifesciences
    • Pharma
    • Healthcare
    • Fitness
    • Nutrition
  • Contact Us
  • About Us
  • Magazines
  • Blogs
    • HealthTech
    • Lifesciences
    • Pharma
    • Healthcare
    • Fitness
    • Nutrition
  • Contact Us

The Lifesciences Magazine

Zenex International - The Bridge Between Hospitals & Posologist | Mr. V.V. Mannapur | The Lifesciences Magazine

Zenex International – The Bridge Between Hospitals & Posologist

Hyprevention - Making Healthcare a Better Experience | Cécile VIENNEY | The Lifesciences Magazine

Hyprevention – Making Healthcare a Better Experience

CEMPIA - Revolutionizing the Healthcare Industry | Anupam Chatterjee | The Lifesciences Magazine

CEMPIA – Revolutionizing the Healthcare Industry

Picosun | Macroscopic & Photonics Industry | Jussi Rautee | The Lifesciences Magazine

Picosun – Boon to Macroscopic & Photonics Industry

Ulatus - Pioneer of Language Solution | Shilpa Mittal | The Lifesciences Magazine

Ulatus – Pioneer of Language Solution

Vocera Communications - Stressbusters for Community | The Lifesciences Magazine

Vocera Communications – Stressbusters for Community

Biostadt India Limited | Mr. Juzar Khorakiwala | The Lifesciences Magazine

Biostadt India Limited – Beginning of the New Reign of Farming

Sisco Research Laboratories | S.K. Agarwal | The Lifesciences Magazine

Sisco Research Laboratories- At the Forefront of Indian Research and Laboratory Space Since 1975

Delaware Health Information Network - Prioritizing Lives | Dr Jan Lee | The Lifesciences Magazine

Delaware Health Information Network- Prioritizing Lives with Health Networking

MaxMD- Leveraging the Power of IT in Healthcare | Mr. Scott Finlay | The Lifesciences Magazine

MaxMD- Leveraging the Power of IT in Healthcare

Phronetik - Pioneer in Life Science Industry | Tania Martin | The Lifesciences Magazine

Phronetik – Pioneer in Life Science Industry

Natura Biotechnol - Botanical Solution | Pankaj Varshney | The Lifesciences Magazine

Natura Biotechnol – Comprehensive Botanical Solution

Axendia- Revolutionizing Medical Sciences | Daniel Matlis | The Lifesciences Magazine

Axendia- Revolutionizing Medical Sciences with Analytics

Scribe Technology Solutions | Mark D. Boyce | The Lifesciences Magazine

Scribe Technology Solutions – Path towards better Healthcare

Think Biosolution - Specialized Monitoring Platforms | Shourjya Sanyal | The Lifesciences Magazine

Think Biosolution – Creating Specialized Monitoring Platforms

Previous157158159160
The Lifesciences Magazine Logo White

The Lifesciences Magazine is a global healthcare solutions platform that paves the way for various healthcare innovations, expert advice, and the success stories of professionals in the field who are driving transformation with their innovative thinking.

Linkedin X-twitter Medium Reddit

Category

  • Healthtech
  • Lifesciences
  • Pharma
  • Healthcare
  • Fitness
  • Nutrition

Newsletter

Send us a newsletter to get update

  • matthew@thelifesciencesmagazine.com
  • +1 (669) 303 8539
  • San Jose, California

Latest Updates

Shingrix Vaccine Linked to Lower Heart Attack and Stroke Risk | The Lifesciences Magazine

Shingrix Vaccine Linked To Lower Heart Attack And Stroke Risk

Dengue Cases Rise in Tampa Bay: 15 Local Cases Reported | The Lifesciences Magazine

Dengue Cases Rise In Tampa Bay As Infected Mosquitoes Test Positive

Thyroid Tablets Recalled Nationwide Over Superpotency Concerns Key Takeaway: Vitruvias recalled one lot of 30 mg thyroid tablets nationwide over potential superpotency concerns. Affected products: Lot No. 504950, NDC 69680-166-00, expiring Sept. 30, 2026. Patients should not stop treatment on their own and should contact their health care provider for guidance. Vitruvias Therapeutics Inc. is recalling one lot of 30 mg thyroid tablets nationwide after testing found they could be superpotent, the FDA said Aug. 24, potentially exposing patients to excessive thyroid hormone in the latest thyroid tablets recall to draw federal scrutiny. FDA identifies recalled thyroid tablets The recall covers Thyroid Tablets, USP 30 mg, lot No. 504950, with National Drug Code 69680-166-00 and an expiration date of Sept. 30, 2026. The affected lot was distributed nationwide in the United States from Jan. 31 through Sept. 30, 2025. Vitruvias released 3,655 units of the affected lot, with 1,955 sold, according to the FDA notice. The company is voluntarily recalling the product to the consumer level and has notified wholesalers to stop distributing it. The FDA listed the recall Aug. 24 after the company announced it Aug. 21. The agency said the recall is being conducted with its knowledge. Superpotency may cause health problems Testing confirmed the tablets have the potential to contain more thyroid hormone than intended. Taking superpotent thyroid tablets can cause hyperthyroidism, or an overactive thyroid, according to the FDA. Possible effects include weight loss, heat intolerance, fatigue, nervousness, muscle weakness, high blood pressure, chest pain, rapid heart rate, and heart rhythm disturbances. The FDA said older adults, pregnant women and infants face greater risks, particularly with prolonged exposure. "Consumption of superpotent Thyroid tablets can cause hyperthyroidism," the FDA notice says, warning that excessive thyroid hormone can have serious effects on the heart and other body systems. Thyroid, USP is a natural thyroid preparation derived from porcine thyroid glands. It contains levothyroxine and liothyronine and is used to treat hypothyroidism, or an underactive thyroid, the condition this thyroid tablets recall is meant to safely treat. Patients should contact their providers Vitruvias said it has not received reports of adverse events known to be related to the recalled lot, according to the FDA. Patients taking the affected tablets should not stop treatment without first contacting their health care provider for guidance or a replacement prescription. Consumers with questions can contact Vitruvias Therapeutics at safety@vitruvias.com or 256-239-9373, Monday through Friday from 9 a.m. to 5 p.m. Central Time. The FDA also advises people who experience problems that may be related to the medicine to contact their health care provider and report adverse reactions through its MedWatch program. Anyone affected by this thyroid tablets recall should confirm their lot number before altering their routine.

Thyroid Tablets Recalled Nationwide Over Superpotency Concerns

Copyright ©2026: The Lifesciences Magazine | All rights reserved.
  • Disclaimer
  • Privacy Policy
  • Terms & Conditions

We use cookies to improve your experience and also collect some information using Google Analytics. By clicking “Accept “, you agree to this. You can find out more about our use of Cookies.

Accept & Close